Review
[Front line of management of hyperphosphatemia in hemodialysis patients]
[Article in
Japanese]
Affiliations
- PMID: 15577041
Item in Clipboard
Review
[Front line of management of hyperphosphatemia in hemodialysis patients]
[Article in
Japanese]
Clin Calcium.
2004 May.
Abstract
Management of hyperphosphatemia in hemodialysis patients is very important to prevent progress of renal hyperparathyroidism or ectopic calcification. Sevelamer hydrochloride is a Ca and Al free phosphate binder, and reduces serum phosphorus level, without any influence on serum Ca level, and Ca-P products. This compound is expected to reduce the incidence of arterial calcification, and improve the QOL (quality of life) of hemodialysis patients.
Similar articles
-
[Evolution in vitamin D treatment after debut of sevelamer hydrochloride in chronic renal failure patients].Clin Calcium. 2004 Sep;14(9):60-3. Clin Calcium. 2004. PMID: 15577112 Review. Japanese.
-
[Sevelamer hydrochloride prevents ectopic calcification of blood vessels].Clin Calcium. 2004 Jun;14(6):116-22. Clin Calcium. 2004. PMID: 15577065 Review. Japanese.
-
Influence of sevelamer hydrochloride on serum concentration of whole (1-84) and N-terminally truncated (7-84) parathyroid hormone fragments in hemodialysis uremic patients.J Nephrol. 2003 Sep-Oct;16(5):710-5. J Nephrol. 2003. PMID: 14733418 Clinical Trial.
-
Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients.Adv Ren Replace Ther. 2003 Apr;10(2):133-45. doi: 10.1053/jarr.2003.50016. Adv Ren Replace Ther. 2003. PMID: 12879374
-
Slowing the progression of vascular calcification in hemodialysis.J Am Soc Nephrol. 2003 Sep;14(9 Suppl 4):S310-4. doi: 10.1097/01.asn.0000081666.10967.05. J Am Soc Nephrol. 2003. PMID: 12939387 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous